First-ever rapid-acting insulin. This approval extends to a 3-milliliter single-patient-use prefilled pen and a 10-milliliter ...

Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.

The biosimilars reach the US market as the US insulin space has seen seismic changes in the last few years, with a clamour of ...

The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog ...

Treating older people with diabetes is challenging due to multiple medical comorbidities that might interfere with patients' ...

The U.S. Food and Drug Administration (FDA) recently approved Merilog (insulin-aspart-szjj) as the first rapid-acting insulin ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Announcing a new article publication for BIO Integration journal. Diabetes, a common metabolic condition, poses a substantial health burden worldwide. To revolutionize diabetes management, enhance ...

Insulin allows cells to absorb and use glucose. In people with insulin resistance, the cells are unable to use insulin effectively. Insulin resistance occurs when cells in the body do not respond ...

School of Science, Asymmetric Synthesis and Chirotechnology Key Laboratory of Sichuan Province, Xihua University, Chengdu 610039, P. R. China ...

This human insulin analogue that comes in disposable pens prefilled with 1, 1.5, or 3 mL, dosed in 10-unit increments1 binds reversibly to albumin, which extends its half-life to around 7 days. Steady ...